NADAC turns up in three arguments a pharmacy owner has regularly: whether a MAC is defensible, whether the purchasing is competitive, and increasingly whether a state reimbursement floor has been met. It carries real weight in all three, and it is routinely misused in all three as well.
Worth being precise about what it actually is.
How the number is produced
The National Average Drug Acquisition Cost is published by CMS, with Myers and Stauffer LC under contract to run the underlying Retail Price Survey. The survey collects invoice-level acquisition data from a randomly selected sample of retail community pharmacies, independents and chains, on a monthly cycle. Files are refreshed weekly, with a comparison file showing what changed.
Four features of that construction determine where the number is reliable.
It is voluntary. Sampled pharmacies choose whether to respond. There is no penalty for declining and no payment for participating. The representativeness of any given month’s rate is a function of who happened to send invoices back.
It covers retail community pharmacy only. Specialty pharmacies are not surveyed. Neither are institutional or purely mail settings. A NADAC on a limited-distribution product is thin by construction.
340B purchases are excluded by instruction. The survey instrument tells respondents not to submit 340B-priced invoices, and identifiable ones are removed from the calculation.
It reflects invoice price, not fully net cost. Off-invoice discounts and rebates are not collected as separate parameters. Your generic compliance rebate, your prompt-pay terms and your GPO arrangements are not in the number, and they are the difference between invoice cost and what the drug really costs you.
That last point cuts both ways. It means NADAC can sit above your true net cost on generics where you buy well, and it means the survey does not systematically overstate what pharmacies pay.
What NADAC is not
It is not your cost. It is a national average built from other pharmacies’ invoices.
It is not a real-time signal. Even with weekly file publication, the underlying survey is monthly and a rate only moves when responses move it. During a shortage or a sudden supply disruption, the market price and the published NADAC can diverge for weeks.
It is not AWP or WAC. Those are list benchmarks published by compendia and manufacturers. NADAC is an attempt to measure what is actually paid. Conflating them is the most common analytical error in this area.
It is not, on its own, a commercial reimbursement ceiling or floor. Where a NADAC-based floor exists, it exists because a specific programme or statute put it there.
Where NADAC now has legal force
This is the part of the landscape that has changed fastest, and it is genuinely in flux.
Many state Medicaid fee-for-service programmes have used NADAC as the ingredient cost basis for years, paired with a state professional dispensing fee. That pairing is why Medicaid FFS often reimburses closer to true cost than commercial does.
Since 2024 a growing number of states have extended NADAC-based floors beyond Medicaid. Frier Levitt’s survey of 2026 state reform activity lists Kentucky at NADAC plus a $10.64 dispensing fee effective 1 January 2025, Iowa’s SF 383 at NADAC plus $10.68 for contracts beginning 1 July 2025, Nebraska at the Medicaid NADAC methodology plus $10.38 for independents with six or fewer locations, and California at NADAC plus $10.05 for the Medi-Cal rate from October 2025, with NADAC-plus provisions also enacted in Arkansas, Georgia, Tennessee and West Virginia and pending in others.
The important caveat: these laws are being litigated. A federal court enjoined significant parts of Iowa’s law on ERISA preemption grounds. The Supreme Court’s decision in Rutledge v. PCMA in 2020 upheld Arkansas’s MAC floor as cost regulation, while the Tenth Circuit in PCMA v. Mulready held that ERISA preempted Oklahoma provisions that dictated network design, and the Supreme Court declined to review that decision in June 2025. The practical read is that a state can generally set what you are paid but has a harder time dictating how a plan builds its network. Which of your plans a given floor reaches is a question for your own counsel and depends on whether the plan is self-funded.
Where NADAC is genuinely useful
As evidence in a MAC appeal. A MAC set below a published national average acquisition cost is a straightforward argument, and it is one that does not require you to disclose your own contract terms. Most PBM appeal forms ask for your invoice cost net of discounts. NADAC does not replace that, it corroborates it.
As a purchasing check. If your net cost on a high-volume generic sits meaningfully above NADAC, the problem is upstream of the PBM. That is a wholesaler conversation, a source change, or a generic compliance rate you are not hitting. Blaming the contract for a purchasing gap wastes the appeal window.
As a triage sort. Ranking claims by paid amount against NADAC for the same NDC and unit gives you a defensible worklist in seconds, which matters because appeal deadlines at several PBMs run in business days from the initial claim.
As a floor test where a floor exists. If you operate in a state with a NADAC-plus statute, you now need the comparison as a compliance check on the payer, not just as an internal metric.
The trap that produces false variances
Unit of measure. NADAC is published per unit with a stated unit type: each, millilitre, gram. Your claim carries quantity dispensed in metric decimal units. Getting the conversion wrong turns a correctly paid claim into an alarming variance and buries the real ones in noise.
The categories that break most often are creams and ointments billed in grams against package sizes in tubes, inhalers and nasal sprays where the billing unit is the device or the millilitre depending on the product, insulin pens billed in millilitres, and kits. If you are building this comparison yourself, validate a sample of each of those by hand before you trust the report.
The second trap is NDC formatting. NADAC publishes the 11-digit NDC. Your dispensing system may hold a 10-digit form with different segment padding. Leading-zero normalisation errors will silently drop your highest-cost lines.
The comparison worth having
The useful artefact is not a NADAC report. It is a per-claim triple: what you were paid, what the drug actually cost you net, and what the national benchmark says it should have cost. One row per claim, joined on NDC and date of service, available while the appeal window is still open.
Attergo Intelligence maintains that comparison continuously against the live claim stream, which is what makes NADAC an operational input rather than a monthly export. Whether you automate it or build it in a spreadsheet, insist on all three columns. Any two of them will let you argue with the wrong party.